Supplemental Figures S1-S8 from AEG-1 Promoter–Mediated Imaging of Prostate Cancer

S1: Schematic maps of AEG-Prom and PEG-Prom reporter constructs S2: c-MYC protein levels analyzed in prostate cancer cell lines by western blotting using anti-MYC antibody (57-70 kDa) S3: Time course for model maturation with PC3-ML-Luc cells using bioluminescence imaging (BLI) at week 5 after injection of: (A) 5 x 104 cells (intracardiac); (B) 1 x 106 cells (tail vein) S4: Cancer-specific AEG-Prom and PEG-Prom activity shown by bioluminescence imaging (BLI) in an experimental model of human prostate cancer (PC3-ML) S5: Comparison of Luc plasmid delivery to lungs of the PCa group for pAEG-Luc treated and pPEG-Luc treated animals (n = 3, PCa-1-3 in Supplemental Fig. S4), respectively S6: Correlation between AEG-1 promoter-driven Luc expression and metastatic sites by histopathological analysis in a bone metastatic prostate cancer model of prostate cancer metastasis S7: Cancer-Specific AEG-Prom activity shown by bioluminescence imaging (BLI) in experimental models of human prostate cancer (PC3-ML) S8: AEG-Prom-based SPECT/CT imaging detects distant metastasis not identified by NaF- or FDG-PET/CT